# Combined Active Treatment in Type 2 Diabetes with NASH

> **NCT04639414** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **German Diabetes Center** · enrollment: 192 (estimated)

## Conditions studied

- Type 2 Diabetes
- Non-alcoholic Steatohepatitis (NASH)
- Non-alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- **DRUG:** Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
- **DRUG:** Placebo matching empagliflozin and placebo pen injector matching semaglutide

## Key facts

- **NCT ID:** NCT04639414
- **Lead sponsor:** German Diabetes Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-26
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-12
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639414, "Combined Active Treatment in Type 2 Diabetes with NASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04639414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*